10-K · February 26, 2026
Tectonic Therapeutic positions itself as a GPCR-focused, clinical-stage biologics company leveraging its proprietary GEODe™ discovery platform to develop GPCR-targeted proteins and antibodies. The company’s lead asset…
Earnings analysis · 10-Q
TECX earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Tectonic Therapeutic, Inc. (TECX) reported significant financial losses for Q1 2026, with a net loss increasing to $25.2 million from $15.9 million in Q1 2025, demonstrating a substantial 59% year-over-year increase.…
Read full summary
Tectonic Therapeutic, Inc. (TECX) reported significant financial losses for Q1 2026, with a net loss increasing to $25.2 million from $15.9 million in Q1 2025, demonstrating a substantial 59% year-over-year increase. Operating expenses rose sharply, driven primarily by research and development costs related to ongoing clinical trials. The company's cash position remains healthy at $236.9 million; however, uncertainties around effective capital management and compliance obligations present ongoing risks.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Increased Net Loss: $25M Q1 2026
Net loss for Q1 2026 was $(25.2M), up from $(15.9M) in Q1 2025, marking a 59% increase year-over-year.
-
R&D Expenses Surge: $20.9M
Research and development expenses surged to $20.9 million in Q1 2026, up from $13.0 million in Q1 2025, reflecting increased costs for ongoing clinical trials.
-
Operating Cash Flow: $(18.4M)
Operating cash flow for Q1 2026 was $(18.4M), compared to $(13.1M) in Q1 2025.
-
Cash Reserves: $236.9M Maintained
Cash and cash equivalents stood at $236.9 million as of March 31, 2026, down from $254.9 million at the end of 2025.
-
Increase in Outstanding Shares
Outstanding shares increased from 18,738,249 at end of 2025 to 18,830,436 at March 31, 2026.
-
High Dependency on Third-Party Manufacturers
As of Q1 2026, reliance on WuXi Biologics for manufacturing TX45 raises risks of supply chain disruptions.
What to watch
-
Significant Operating Losses
Q1 2026 net loss of $(25.2M) raises concerns over long-term sustainability given continued operational deficits.
-
Regulatory Risks Related to Compliance
Compliance with evolving healthcare and data protection regulations may lead to increased costs and operational disruption.
-
Reliance on Third-Party Suppliers
Dependency on third-party manufacturers, particularly in politically sensitive regions, may jeopardize supply chain integrity if disruptions occur.
Management's outlook
Outlook deferred to earnings press release / call.
Earlier filings 4
10-Q · November 6, 2025
Tectonic Therapeutic reported a Q3 2025 loss of $19.0 million ($-1.02 EPS) compared to a loss of $17.7 million ($-1.20 EPS) in Q3 2024. The company continues to experience significant cash burn, reporting net cash used…
10-Q · August 7, 2025
Tectonic Therapeutic reported a Q2 net loss of $19.98 million (‑$1.07 per share) vs. a loss of $12.67 million in Q2 2024, driven by higher R&D and G&A spend. Liquidity materially improved after a private placement that…
10-Q · August 14, 2024
Tectonic completed a reverse recapitalization/merger on June 20, 2024 and raised material cash from a Subscription Agreement and the Merger, leaving cash and equivalents of $185,124 (in thousands) as of June 30, 2024.…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.